Category Archives: Stem Cell Research

Public release date: 11-Apr-2013 [ | E-mail | Share ] Contact: Kevin Mayhood kevin.mayhood@case.edu 216-368-4442 Case Western Reserve University Stem cells can be coaxed to grow into new bone or new cartilage better and faster when given the right molecular cues and room inside a water-loving gel, researchers at Case Western Reserve University show. By creating a three-dimensional checkerboardone with alternating highly connected and less connected spaces within the hydrogelthe team found adjusting the size of the micropattern could affect stem cell behaviors, such as proliferation and differentiation. Inducing how and where stem cells growand into the right kind of cell in three dimensionshas proven a challenge to creating useful stem cell therapies. This technique holds promise for studying how physical, chemical and other influences affect cell behavior in three-dimensions, and, ultimately, as a method to grow tissues for regenerative medicine applications. "We think that control over local biomaterial properties may allow us to guide the formation of complex tissues," said Eben Alsberg, an associate professor of Biomedical Engineering at Case Western Reserve. "With this system, we can regulate cell proliferation and cell-specific differentiation into, for example, bone-like or cartilage-like cells." Oju Jeon, PhD, a postdoctoral researcher in Biomedical Engineering, … Continue reading →

3D printer can build synthetic tissues A custom-built programmable 3D printer can create materials with several of the properties of living tissues, Oxford University scientists have demonstrated. By: Alton Parrish … Continue reading →

iGUIDE TODAY: Roger Ebert, Jay Leno, LEGOLand This week, the P-E staff discuss the big entertainment stories of the week including the death of film critic Roger Ebert, Jimmy Fallon taking over "The Toni... By: pe … Continue reading →

Riverside Air Show Takes Off The Riverside Municipal Airport held its 21st Riverside Air show on Saturday, April 6. For more on this story and other breaking news in Inland Southern Cali... By: pe … Continue reading →

CRIME BLOTTER: Dog tied to train tracks saved by engineer in Mecca A puppy that was left tied to railroad tracks was saved from certain death when the engineer of the approaching train spotted a man walking away from the tra... By: pe … Continue reading →

ALAMEDA, Calif.--(BUSINESS WIRE)-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it is now offering 100 selected ProSpec-Tany TechnoGene (ProSpec) manufactured recombinant proteins related to stem cell research in its recently launched LifeMap BioReagents portal (http://bioreagents.lifemapsc.com) to researchers worldwide. ProSpecs innovative recombinant proteins, including growth factors, signaling molecules, differentiation factors, hormones, cytokines and chemokines will complement the current BioTime research product lines available via LifeMap BioReagents, including BioTimes PureStem human progenitor cell lines, PureStem packages, clinical and research grade human embryonic stem cell lines (hES), ESpan growth media for progenitor cell lines, and cell differentiation media. The addition of ProSpec products reflects LifeMap Sciences execution of its strategy to market a growing catalog of research products to aid scientists in a variety of fields, including stem cell research, developmental biology, mechanisms of various human diseases and drug and therapeutic discovery. LifeMap Sciences holds an exclusive, worldwide license to market GeneCards (www.genecards.org), the human gene compendium, and MalaCards (www.malacards.org), a database with nearly 17,000 human disease entries, from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science. Additionally, it has recently launched version 1.1 of LifeMap Discovery, a comprehensive … Continue reading →

Vatican City Wading into one of the most controversial fields of modern medicine, the Vatican is pushing adult stem cell research as ethical and scientifically more promising than embryonic stem cell research. That's despite assertions from many in the scientific community that that it's important to pursue all types of stem cell research, including embryonic, to maximize chances of finding cures for diseases. Harvesting embryonic stem cells requires the destruction of fertilized embryos -- which are considered nascent human life in Catholic doctrine. Adult stem cells can be safely taken from adult human beings. The Vatican started promoting adult stem cells in 2011, when its Pontifical Council for Culture launched a collaboration with U.S. bio-pharmaceutical company NeoStem. The Council will host its second major conference on the issue at the Vatican this week (April 11-13), with the aim of publicizing recent research and shedding the Catholic Church's anti-science reputation. "People don't have to choose between life and science," said Robin Smith, CEO of New York-based NeoStem and president of its nonprofit arm, the Stem for Life Foundation. "We want to correct the misunderstanding in public opinion on adult stem cells. People need to understand how far we are with research." … Continue reading →

TORONTO, ONTARIO--(Marketwired - Apr 9, 2013) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT"), a life sciences company developing stem cell-related technologies, today announced that it has completed its merger with Trillium Therapeutics Inc. ("Trillium") previously announced on February 4, 2013. The shareholders of Trillium voted overwhelmingly to support the merger. The company also announced the issuance of 2,560,197 stock options under its stock option plan to directors, officers and employees reflecting the addition of the executives and staff of the merged entity. The options have an exercise price of $0.25 and a term of ten years. The issuance of stock options is subject to acceptance by the TSX Venture exchange. About Stem Cell Therapeutics: Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) develops stem cell-based therapeutics through partnerships with research institutions and technology transfer organizations. SCT's objectives include the sourcing and acquisition of stem cell-related development opportunities, and securing capital for the advancement of its licensed or acquired products. The Corporation's intended corporate acquisitions and licensed acquisitions are positioning it principally in the field of cancer stem cell therapeutic development. SCT is a member of the Centre for Commercialization of Regenerative Medicine consortium. For more information, visit: http://www.stemcellthera.com. Forward Looking Statements … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the "Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2013" report to their offering. 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cell Transplantation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation. - A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hematopoietic Stem Cell Transplantation pipeline … Continue reading →

What research is there to support the use of fecal transplant? Many people in the U.S. are just beginning to find out about how effective fecal transplant can be to treat Ulcerative Colitis in addition to infections caus... By: Michael Hurst … Continue reading →